Revised SPC: Tivicay (dolutegravir) 5 mg dispersible tablets

This new formulation is available for the treatment of HIV in patients aged ≥4 weeks and weighing ≥3 kg, or for those in whom film-coated (FC) tablets are not appropriate. The bioavailability of dispersible tablets and FC tablets is not comparable.

Source:

electronic Medicines compendium